Olfaction and Nasal Masses

Define the four Greek-derived terms for smell dysfunction: Anosmia, Hyposmia, Hyperosmia, and Dysosmia (including Parosmia and Phantosmia).

Anosmia is complete loss of smell; Hyposmia is partial loss of smell; Hyperosmia is enhanced smell sensitivity.

Dysosmia is a distortion in odor perception, an umbrella term including Parosmia (distorted perception in the presence of an external stimulus, e.g., coffee smells like garbage) and Phantosmia (smell perception with no external stimulus, an olfactory hallucination).

Differentiate Conductive Anosmia from Sensorineural Anosmia, including their common causes.

Conductive Anosmia results from a physical obstacle preventing odorants from reaching the olfactory epithelium or altered mucus properties; common causes include allergic rhinitis, rhinosinusitis (with/without polyposis), illicit drugs (cocaine), and septal deviation (rarely causing complete loss).

Sensorineural Anosmia results from impaired olfactory epithelium function or a disrupted neuronal pathway; common causes include post-viral olfactory loss, neurodegenerative disorders (Parkinson's, Alzheimer's), psychiatric disorders, and head injury.

Describe Kallmann's Syndrome and list the neurological/psychiatric causes of anosmia.

Kallmann's Syndrome is a genetically determined congenital isolated anosmia where patients fail to develop olfactory bulbs, predominantly affecting males and associated with hypogonadotropic hypogonadism.

Neurological causes include Epilepsy (seizures producing brief, vivid, unpleasant olfactory hallucination auras) and Meningitis (especially in infancy); psychiatric causes include depression, hysteric conversion reactions, and schizophrenia; autoimmune causes include Sjögren's syndrome.

List the categories of medications that can cause anosmia or dysosmia (5% of cases), and describe congenital/surgical causes.

Medication categories include: antidepressants/anticonvulsants, antihistamines/cold medications (chlorpheniramine, loratadine, pseudoephedrine), antihypertensives/cardiac drugs (captopril, propranolol, diltiazem), anti-inflammatories, antimicrobials (ampicillin, ciprofloxacin, tetracyclines), antineoplastics (cisplatin, methotrexate), bronchodilators, lipid-lowering drugs, muscle relaxants/Parkinsonism drugs (levodopa), and vasodilators.

Congenital causes (2%) involve fetal developmental failure of olfactory nerves (can be genetically transmitted); surgical causes include cranial surgery, anesthesia complications, or transsphenoidal surgery; heavy smoking can also impair taste via oral mucosa drying.

Describe the clinical evaluation approach and objective smell testing methods for anosmia.

Clinical evaluation includes history/physical exam (including drug history), seizure history (EEG if olfactory auras suspected), otolaryngologic consultation with nasal endoscopy (to rule out polyps/masses/blockage), and Trigeminal assessment (since trigeminal receptors can cross-talk with olfactory perception).

Objective testing includes Smell Identification Tests (UPSIT, Pocket Smell Test), Smell Threshold Tests, the Olfactometer (isolated testing room with HEPA/carbon filtration), and electrophysiological studies (EOG measuring olfactory epithelium potentials, OERP measured from the scalp, and EEG studying alpha wave response to aromatherapy).

Describe the clinical features, prognosis, and pathological differentiation of COVID-19-related loss of smell versus Allergic Rhinitis.

COVID-19 causes sudden loss of smell in 50% of patients, often as an isolated symptom, with a high recovery rate (90% improve within 6 weeks); a positive COVID test with isolated anosmia needs no further investigation.

Compared to Allergic Rhinitis (no receptor damage, usually reversible/recurrent, mild dysosmia), COVID-19 may show receptor damage with neuritis, is reversible only if limited to neuritis (irreversible if frank receptor damage occurs), and causes severe dysosmia.

Describe the management protocol for COVID-19-related loss of smell, including the key contraindication.

For patients with nasal symptoms lasting over 2 weeks: olfactory training is highly recommended, topical nasal steroids are recommended, and steroid drops/rinses are optional.

For isolated loss of smell (no nasal symptoms) over 2 weeks: olfactory training (via resources like AbScent/Fifth Sense) is recommended, omega-3 supplements are optional, Vitamin A drops are controversial, and Alpha Lipoic Acid is not recommended.

Critically, Oral Corticosteroids are absolutely contraindicated in the acute stage, and only considered optional after total resolution of other COVID symptoms for persistent isolated loss of smell.

Describe the anatomical classification of Nasal Masses by location (Midline, Unilateral by wall, and Bilateral).

Midline masses include Septal Hematoma, Septal Tumors, Encephalocele, and Meningocele.

Unilateral masses vary by location:
Inside the cavity (endonasal, e.g., foreign body, where a probe passes entirely around it), Septum (small hemangiomas, bleeding polyps), Floor (nasoalveolar cysts pushing the nose upward), Lateral Wall (inverted papilloma, angiofibroma, malignancies), and Roof (encephaloceles/meningoceles, intracranial tissue herniation — never biopsy a roof mass due to CSF rhinorrhea risk).

Bilateral masses include Ethmoidal Polyposis, Adenoids, and Hypertrophied Inferior Turbinate.

Compare Angiofibroma, Inverted Papilloma, and Antrochoanal Polyp as lateral wall nasal masses.

Angiofibroma is a vascular tumor covered with petechiae, strictly "do not touch" (biopsy contraindicated due to bleeding risk), predominantly affecting young males, managed via specific non-biopsy protocols.

Inverted Papilloma is a benign tumor with a 10-15% risk of malignant transformation, an irregular fleshy surface, requiring mandatory surgical removal.

Antrochoanal Polyp is an absolutely benign inflammatory lesion originating in the maxillary sinus and entering the nasal cavity, with a smooth grayish surface, predominantly affecting children/youth, treated with surgical removal.

Describe the clinical examination methods for nasal masses and the behavior/extension patterns of malignant nasal tumors.

Examination methods include direct visual inspection (outpatient standard), flexible endoscopy (reaches nasopharynx/choana, determines mass origin), CT scan (minimum imaging standard; plain X-ray is obsolete), and the Probe Test (a blunt metal rod passed around the mass to locate its origin).

Malignancies (squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, melanoma, etc.) do not respect anatomical walls or natural ostia, extending downward (eroding the palate/mouth), upward (to the eye, causing ophthalmoplegia), or outward (to the cheek, creating skin fistulas), plus broadening the nose and eroding bone.

Describe Septal Hematoma, including its etiology, pathophysiology, complications, and management.

Septal Hematoma results from direct nasal trauma (falls, sports injuries), presenting as a red midline mass with nasal blockage (often noticed at night).

The mucosa detaches from cartilage, blood collects in the space, stripping the perichondrium and causing cartilage to lose blood supply and die. If untreated, it becomes infected (Septal Abscess), which eats the cartilage and causes structural collapse ("Saddle Nose Deformity"). Management requires immediate Incision and Drainage, with no medical treatment and no waiting for swelling to subside.

Describe Diffuse Sinonasal Polyposis, its treatment protocol, and the concept of Functional Endoscopic Sinus Surgery (FESS).

Diffuse Sinonasal Polyposis presents as multiple bilateral nasal polyps (a form of sinusitis) of unknown etiology (theories include drug sensitivity, autoimmune imbalance, mucosal contact); treatment follows primary medical management, then surgical intervention (FESS), then immediate resumption of medical therapy post-surgery.

Biologic therapy is highly effective but extremely expensive (two injections every 15 days, for 2 years to lifelong). FESS restores normal sinus physiology by opening a small hole at the exact natural ostium (rather than breaking sinus walls as in obsolete traditional surgery), allowing programmed mucociliary secretions to drain properly; red flags for nasal masses include persistent unilateral obstruction/rhinorrhea/epistaxis/pain, cranial nerve involvement, and extra-nasal extensi